Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04318470 · ClinicalTrials.gov registry record
Identification of Microbial DNA in Maternal Plasma After PPROM
A clinical trial of Preterm Rupture of Membranes, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 70
- Enrollment target
- 1
- Study location
NCT04318470: Completed study of Preterm Rupture of Membranes, sponsored by University of California, San Francisco.
NCT04318470 is a study of Preterm Rupture of Membranes that has completed, run by University of California, San Francisco. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04318470, a study of Preterm Rupture of Membranes, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the use of metagenomic next generation sequencing in identifying microbial DNA in plasma samples of patients with preterm premature rupture of membranes.
Primary Outcome
Time between PPROM and delivery
Conditions Studied
Interventions
- DIAGNOSTIC_TEST mNGS
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2022-12-31 |
What the finished NCT04318470 record still lists
NCT04318470 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 1 condition, with Preterm Rupture of Membranes appearing as the primary indexed condition, and to 1 intervention - of which mNGS is the first listed.
NCT04318470 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04318470 about?
NCT04318470 is a clinical study titled "Identification of Microbial DNA in Maternal Plasma After PPROM". This study evaluates the use of metagenomic next generation sequencing in identifying microbial DNA in plasma samples of patients with preterm premature rupture of membranes.
What is the current status of trial NCT04318470?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2020-02-12. Estimated completion is 2022-12-31.
What conditions does trial NCT04318470 study?
This clinical trial studies the following conditions: Preterm Rupture of Membranes.
What interventions are being tested in trial NCT04318470?
The interventions under investigation include: mNGS (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04318470?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04318470 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI